Novartis’ ofatumumab data comparable to Ocrevus in RRMS

Roche’s blockbuster MS therapy Ocrevus ocrelizumab could soon have company in relapsing-remitting multiple sclerosis as Phase III data presented Friday for ofatumumab by Novartis show the two anti-CD20 mAbs could have comparable efficacy.

Data from the ASCLEPIOS I and II studies showed once-monthly subcutaneous injections of ofatumumab met the primary endpoint with a reduction in relapse rates of 50.5% and 58.8% vs. the active control of Aubagio teriflunomide (P<0.001 in both studies). ...